Effect of Fuzheng Qingdu Therapy for Metastatic Gastric Cancer is Associated With Improved Survival: A Multicenter Propensity-Matched Study

Objective To evaluate the therapeutic effect of Traditional Chinese Medicine (TCM), specifically Fuzheng Qingdu (FZQD) therapy, on the survival time of metastatic GC patients. Patients and Methods Databases of medical records of 6 hospitals showed that 432 patients with stage IV GC were enrolled fro...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Chao Hou MD, Die Yang BS, Yusen Zhang BS, Yifei Li BS, Zhengfei He MS, Xiaojun Dai MD, Qingyun Lu MS, Shanshan Wang MD, Xiaochun Zhang MD, Yanqing Liu PhD
Formato:	article
Lenguaje:	EN
Publicado:	SAGE Publishing 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/cc09651a9305496c9906ccc613f4a9bc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:cc09651a9305496c9906ccc613f4a9bc
record_format	dspace
spelling	oai:doaj.org-article:cc09651a9305496c9906ccc613f4a9bc2021-11-17T00:03:19ZEffect of Fuzheng Qingdu Therapy for Metastatic Gastric Cancer is Associated With Improved Survival: A Multicenter Propensity-Matched Study1534-73541552-695X10.1177/15347354211058464https://doaj.org/article/cc09651a9305496c9906ccc613f4a9bc2021-11-01T00:00:00Zhttps://doi.org/10.1177/15347354211058464https://doaj.org/toc/1534-7354https://doaj.org/toc/1552-695XObjective To evaluate the therapeutic effect of Traditional Chinese Medicine (TCM), specifically Fuzheng Qingdu (FZQD) therapy, on the survival time of metastatic GC patients. Patients and Methods Databases of medical records of 6 hospitals showed that 432 patients with stage IV GC were enrolled from March 1, 2012 to October 31, 2020. Propensity score matching (PSM) was used to reduce the bias caused by confounding factors in the comparison between the TCM and the non-TCM users. We used a Cox multivariate regression model to compare the hazard ratio (HR) value for mortality risk, and Kaplan-Meier survival curve for the survival time of GC patients Results The same number of subjects from the non-TCM group were matched with 122 TCM-treated patients after PSM to evaluate their overall survival (OS) and progression-free survival (PFS). Median time of OS of TCM and non-TCM users were 16.53 and 9.10 months, respectively. TCM and non-TCM groups demonstrated a 1-year survival rate of 68.5% and 34.5%, 2-year survival rate of 28.6% and 3.5%, and 3-year survival rate of 17.8% and 0.0%, respectively. A statistical difference exists in OS between the 2 groups (χ 2 = 33.39 and P < .0001). The PFS of TCM users was also longer than that of non-TCM users (χ 2 = 4.95 and P = 0.026). Notably, Chinese herbal decoction, Shenmai and compound Kushen injections were commonly used for FZQD therapy. Conclusion This propensity-matched study showed that FZQD therapy could improve the survival of metastatic GC patients.Chao Hou MDDie Yang BSYusen Zhang BSYifei Li BSZhengfei He MSXiaojun Dai MDQingyun Lu MSShanshan Wang MDXiaochun Zhang MDYanqing Liu PhDSAGE PublishingarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENIntegrative Cancer Therapies, Vol 20 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Chao Hou MD Die Yang BS Yusen Zhang BS Yifei Li BS Zhengfei He MS Xiaojun Dai MD Qingyun Lu MS Shanshan Wang MD Xiaochun Zhang MD Yanqing Liu PhD Effect of Fuzheng Qingdu Therapy for Metastatic Gastric Cancer is Associated With Improved Survival: A Multicenter Propensity-Matched Study
description	Objective To evaluate the therapeutic effect of Traditional Chinese Medicine (TCM), specifically Fuzheng Qingdu (FZQD) therapy, on the survival time of metastatic GC patients. Patients and Methods Databases of medical records of 6 hospitals showed that 432 patients with stage IV GC were enrolled from March 1, 2012 to October 31, 2020. Propensity score matching (PSM) was used to reduce the bias caused by confounding factors in the comparison between the TCM and the non-TCM users. We used a Cox multivariate regression model to compare the hazard ratio (HR) value for mortality risk, and Kaplan-Meier survival curve for the survival time of GC patients Results The same number of subjects from the non-TCM group were matched with 122 TCM-treated patients after PSM to evaluate their overall survival (OS) and progression-free survival (PFS). Median time of OS of TCM and non-TCM users were 16.53 and 9.10 months, respectively. TCM and non-TCM groups demonstrated a 1-year survival rate of 68.5% and 34.5%, 2-year survival rate of 28.6% and 3.5%, and 3-year survival rate of 17.8% and 0.0%, respectively. A statistical difference exists in OS between the 2 groups (χ 2 = 33.39 and P < .0001). The PFS of TCM users was also longer than that of non-TCM users (χ 2 = 4.95 and P = 0.026). Notably, Chinese herbal decoction, Shenmai and compound Kushen injections were commonly used for FZQD therapy. Conclusion This propensity-matched study showed that FZQD therapy could improve the survival of metastatic GC patients.
format	article
author	Chao Hou MD Die Yang BS Yusen Zhang BS Yifei Li BS Zhengfei He MS Xiaojun Dai MD Qingyun Lu MS Shanshan Wang MD Xiaochun Zhang MD Yanqing Liu PhD
author_facet	Chao Hou MD Die Yang BS Yusen Zhang BS Yifei Li BS Zhengfei He MS Xiaojun Dai MD Qingyun Lu MS Shanshan Wang MD Xiaochun Zhang MD Yanqing Liu PhD
author_sort	Chao Hou MD
title	Effect of Fuzheng Qingdu Therapy for Metastatic Gastric Cancer is Associated With Improved Survival: A Multicenter Propensity-Matched Study
title_short	Effect of Fuzheng Qingdu Therapy for Metastatic Gastric Cancer is Associated With Improved Survival: A Multicenter Propensity-Matched Study
title_full	Effect of Fuzheng Qingdu Therapy for Metastatic Gastric Cancer is Associated With Improved Survival: A Multicenter Propensity-Matched Study
title_fullStr	Effect of Fuzheng Qingdu Therapy for Metastatic Gastric Cancer is Associated With Improved Survival: A Multicenter Propensity-Matched Study
title_full_unstemmed	Effect of Fuzheng Qingdu Therapy for Metastatic Gastric Cancer is Associated With Improved Survival: A Multicenter Propensity-Matched Study
title_sort	effect of fuzheng qingdu therapy for metastatic gastric cancer is associated with improved survival: a multicenter propensity-matched study
publisher	SAGE Publishing
publishDate	2021
url	https://doaj.org/article/cc09651a9305496c9906ccc613f4a9bc
work_keys_str_mv	AT chaohoumd effectoffuzhengqingdutherapyformetastaticgastriccancerisassociatedwithimprovedsurvivalamulticenterpropensitymatchedstudy AT dieyangbs effectoffuzhengqingdutherapyformetastaticgastriccancerisassociatedwithimprovedsurvivalamulticenterpropensitymatchedstudy AT yusenzhangbs effectoffuzhengqingdutherapyformetastaticgastriccancerisassociatedwithimprovedsurvivalamulticenterpropensitymatchedstudy AT yifeilibs effectoffuzhengqingdutherapyformetastaticgastriccancerisassociatedwithimprovedsurvivalamulticenterpropensitymatchedstudy AT zhengfeihems effectoffuzhengqingdutherapyformetastaticgastriccancerisassociatedwithimprovedsurvivalamulticenterpropensitymatchedstudy AT xiaojundaimd effectoffuzhengqingdutherapyformetastaticgastriccancerisassociatedwithimprovedsurvivalamulticenterpropensitymatchedstudy AT qingyunlums effectoffuzhengqingdutherapyformetastaticgastriccancerisassociatedwithimprovedsurvivalamulticenterpropensitymatchedstudy AT shanshanwangmd effectoffuzhengqingdutherapyformetastaticgastriccancerisassociatedwithimprovedsurvivalamulticenterpropensitymatchedstudy AT xiaochunzhangmd effectoffuzhengqingdutherapyformetastaticgastriccancerisassociatedwithimprovedsurvivalamulticenterpropensitymatchedstudy AT yanqingliuphd effectoffuzhengqingdutherapyformetastaticgastriccancerisassociatedwithimprovedsurvivalamulticenterpropensitymatchedstudy
_version_	1718426074255196160

Effect of Fuzheng Qingdu Therapy for Metastatic Gastric Cancer is Associated With Improved Survival: A Multicenter Propensity-Matched Study

Ejemplares similares